Neurizon Therapeutics (FRA:ECQ0) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Neurizon Therapeutics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Neurizon Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was €2.01 Mil. Neurizon Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was €0.00 Mil. Neurizon Therapeutics's annualized EBITDA for the quarter that ended in Jun. 2026 was €-18.02 Mil. Neurizon Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was -0.11.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Neurizon Therapeutics's Debt-to-EBITDA or its related term are showing as below:

FRA:ECQ0' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.52   Med: -0.33   Max: -0.16
Current: -0.16

During the past 13 years, the highest Debt-to-EBITDA Ratio of Neurizon Therapeutics was -0.16. The lowest was -1.52. And the median was -0.33.

FRA:ECQ0's Debt-to-EBITDA is ranked worse than
100% of 304 companies
in the Biotechnology industry
Industry Median: 1.215 vs FRA:ECQ0: -0.16

Neurizon Therapeutics  (FRA:ECQ0) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Neurizon Therapeutics Debt-to-EBITDA Related Terms

Neurizon Therapeutics Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Neurizon Therapeutics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurizon Therapeutics Debt-to-EBITDA Chart

Neurizon Therapeutics Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Neurizon Therapeutics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

FRA:ECQ0 vs VRTX, REGN, MRNA: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, Neurizon Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neurizon Therapeutics Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neurizon Therapeutics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Neurizon Therapeutics's Debt-to-EBITDA falls into.


Neurizon Therapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Neurizon Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.0063822492784 + 0) / -15.304882578359
=-0.13

Neurizon Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.0063822492784 + 0) / -18.021609612822
=-0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.

Neurizon Therapeutics Business Description

Other Exchanges ECQ0:GermanyNUZ:Australia
Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3205
Neurizon Therapeutics Ltd is a clinical-stage biotech company that develops drug discovery intellectual property for the treatment of different types of neurodegenerative diseases. Its product pipeline is NUZ-001 (S-Monepantel).